Inhibition of human Nav1.4 by D-amino acid modified μ-CnIIIC
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.109484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Renfei Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, …. Hauptthemen laut MEDLINE: NAV1.4 Voltage-Gated Sodium Channel, Amino Acids, Voltage-Gated Sodium Channel Blockers. Die Arbeit nennt 54 Literaturangaben.
Abstract (Originalsprache)
Voltage-gated sodium channel Nav1.4 is a key target for neuromuscular disorders; however, existing peptide inhibitors face stability challenges. We systematically investigated the effect of D-amino acid modification on the inhibition of the human voltage-gated sodium channel NaV1.4 by μ-CnIIIC. The N-terminal pyroglutamic acid (pGlu) of wild-type μ-CnIIIC was replaced with D-arginine (Dar), D-lysine (Dly), or D-histidine (Dhi) via solid-phase peptide synthesis, yielding the derivatives dR-μ-CnIIIC, dK-μ-CnIIIC, and dH-μ-CnIIIC, respectively. Voltage patch clamp experiments demonstrated that dR-μ-CnIIIC, which inhibited NaV1.4 in its resting state, exhibited superior inhibitory activity, with an IC50 valueof 54.14 ± 6.26 nM (P < 0.01) compared to 96.37 ± 10.68 nM for the wild-type peptide. Molecular docking and kinetic simulations revealed that dR-μ-CnIIIC formed strong electrostatic interactions and hydrogen-bonding networks with the hNaV1.4 protein α-subunits Glu352, Asp1514, and Asp1515, as well as the β-subunit Glu48, thereby enhancing its binding affinity. Serum stability assays further demonstrated that D-amino acid modification substantially enhanced the resistance to protease degradation, with dR-μ-CnIIIC retaining 31.7% activity after 480 min. This study provides a rational design strategy for the development of efficient and stable sodium channel-targeted therapeutic agents. Moreover, this D-amino acid substitution strategy may be generalizable to other conotoxin-based therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China; PeptiOrigin Biotechnology Co., Ltd., Shenzhen 518000, China.
- PeptiOrigin Biotechnology Co., Ltd., Shenzhen 518000, China.
- Hubei Key Laboratory of Agricultural Bioinformatics, College of Informatics, Huazhong Agricultural University, Wuhan 430070, PR China.
- Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi 830017, China. Electronic address: mzhxju@xju.edu.cn.
Zitieren
APA
Wu, R., Wang, Z., Quan, Y., He, Z., Zhao, Y., Wang, Y., Wang, J., & Ma, Z. (2026). Inhibition of human Nav1.4 by D-amino acid modified μ-CnIIIC. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109484
Vancouver
Wu R, Wang Z, Quan Y, He Z, Zhao Y, Wang Y, et al. Inhibition of human Nav1.4 by D-amino acid modified μ-CnIIIC. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109484
BibTeX
@article{Wu2026,
author = {Wu, Renfei and Wang, Zhuying and Quan, Yuan and He, Zhen and Zhao, Yingsheng and Wang, Yaya and Wang, Junmei and Ma, Zhenghai},
title = {Inhibition of human Nav1.4 by D-amino acid modified μ-CnIIIC},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.109484}
}
EUVIMED